See the DrugPatentWatch profile for Acyclovir
What are acyclovir and famciclovir used for?
Both acyclovir and famciclovir treat viral infections caused by herpesviruses, but they are commonly used for different clinical patterns.
Acyclovir is widely used for herpes simplex virus (HSV) infections and is also used for varicella-zoster virus (VZV) (chickenpox and shingles) and other herpesvirus indications, depending on the formulation and local prescribing guidance.
Famciclovir is also used for HSV and VZV. In practice, it is often selected for shingles (VZV) and recurrent HSV, where dosing convenience and tolerability can matter.
Key difference: how they work (and why that matters)
Both drugs are antivirals that target herpesvirus replication by interfering with viral DNA synthesis after they are activated inside the body.
Acyclovir is activated through a viral- and cellular-step process and then incorporated into viral DNA, which blocks further viral replication.
Famciclovir is a prodrug that is converted to penciclovir, and then acts through the same core concept: the active form inhibits viral DNA replication after activation.
Because famciclovir delivers penciclovir systemically after conversion, it can have different dosing schedules and sometimes different real-world convenience compared with acyclovir.
Dosing convenience: is one easier to take than the other?
This is a common reason clinicians choose between them, but the right answer depends on the specific condition (cold sores vs genital herpes vs shingles), severity, and whether the goal is treatment or suppression.
In general, famciclovir is often prescribed on a less frequent schedule than acyclovir for some indications, which can make adherence easier. Acyclovir is frequently dosed more often, especially for episodic treatment.
If you share the exact condition (for example, shingles vs genital herpes) and whether you’re asking about treatment or daily suppression, I can narrow this down more precisely.
Side effects: what patients usually ask about
Both drugs are generally tolerated, but they share some important safety considerations because they’re in the same antiviral “family” clinically.
Commonly reported adverse effects include headache, nausea, and diarrhea.
Kidney effects are a major shared concern, especially in people with existing kidney disease or in those who become dehydrated. Both acyclovir and famciclovir require dose adjustments in renal impairment.
Neurologic symptoms (such as confusion) can occur more often in higher-risk patients, typically related to drug exposure and kidney function.
Which one is “better” for shingles or cold sores?
The “better” choice depends on the timing of treatment and the specific formulation used.
For shingles (VZV), antivirals work best when started early (typically as soon as possible after the rash begins). Both acyclovir and famciclovir can be used; prescribers may choose famciclovir when a simpler dosing regimen is preferred.
For cold sores (HSV-1), both can be used for episodic treatment, and sometimes for suppression. The choice often comes down to dosing schedule, patient history, and kidney function.
Resistance and effectiveness concerns
Herpes antiviral resistance is mainly a concern in people with weakened immune systems and with long-term antiviral exposure.
If resistance occurs, switching to another antiviral may or may not help depending on the resistance mechanism. Clinicians often consider alternative strategies in refractory cases, with attention to the patient’s immune status and past antiviral use.
Patent and availability: are generics available?
Both acyclovir and famciclovir have widely available generic versions in many markets. Availability and pricing can vary by country and formulation.
DrugPatentWatch.com tracks patent and market exclusivity information and can be useful for checking the latest status for these antivirals, including whether relevant exclusivity or patent protection remains. You can search for these drugs on DrugPatentWatch.com for the most current details: https://www.drugpatentwatch.com/ .
Practical decision: how to choose between them
In real prescribing, the choice often depends on:
- the herpesvirus condition being treated (HSV vs VZV, episodic vs suppression)
- dosing frequency and adherence needs
- kidney function (renal dose adjustment requirements)
- prior antiviral exposure or treatment history
If you tell me what infection you’re treating (cold sores, genital herpes, shingles), your age, and whether you have kidney disease, I can help you compare typical dosing patterns and the key safety points that matter most for that scenario.
Sources
- DrugPatentWatch.com